101 related articles for article (PubMed ID: 23085456)
1. TGF-beta inhibits human cutaneous melanoma cell migration and invasion through regulation of the plasminogen activator system.
Humbert L; Lebrun JJ
Cell Signal; 2013 Feb; 25(2):490-500. PubMed ID: 23085456
[TBL] [Abstract][Full Text] [Related]
2. Transforming growth factor-beta1 inhibits tumor growth in a mouse melanoma model by down-regulating the plasminogen activation system.
Ramont L; Pasco S; Hornebeck W; Maquart FX; Monboisse JC
Exp Cell Res; 2003 Nov; 291(1):1-10. PubMed ID: 14597403
[TBL] [Abstract][Full Text] [Related]
3. Growth factor-dependent proliferation and invasion of muscle satellite cells require the cell-associated fibrinolytic system.
Fibbi G; D'Alessio S; Pucci M; Cerletti M; Del Rosso M
Biol Chem; 2002 Jan; 383(1):127-36. PubMed ID: 11928807
[TBL] [Abstract][Full Text] [Related]
4. The leukemia inhibitory factor (LIF) and p21 mediate the TGFβ tumor suppressive effects in human cutaneous melanoma.
Humbert L; Ghozlan M; Canaff L; Tian J; Lebrun JJ
BMC Cancer; 2015 Mar; 15():200. PubMed ID: 25885043
[TBL] [Abstract][Full Text] [Related]
5. Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma.
Stabuc B; Markovic J; Bartenjev I; Vrhovec I; Medved U; Kocijancic B
Oncol Rep; 2003; 10(3):635-9. PubMed ID: 12684636
[TBL] [Abstract][Full Text] [Related]
6. Modulation of tissue plasminogen activator and plasminogen activator inhibitor-1 by transforming growth factor-beta in human retinal glial cells.
Schacke W; Beck KF; Pfeilschifter J; Koch F; Hattenbach LO
Invest Ophthalmol Vis Sci; 2002 Aug; 43(8):2799-805. PubMed ID: 12147618
[TBL] [Abstract][Full Text] [Related]
7. Gallic acid inhibits the migration and invasion of A375.S2 human melanoma cells through the inhibition of matrix metalloproteinase-2 and Ras.
Lo C; Lai TY; Yang JS; Yang JH; Ma YS; Weng SW; Lin HY; Chen HY; Lin JG; Chung JG
Melanoma Res; 2011 Aug; 21(4):267-73. PubMed ID: 21734530
[TBL] [Abstract][Full Text] [Related]
8. Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression.
de Vries TJ; Quax PH; Denijn M; Verrijp KN; Verheijen JH; Verspaget HW; Weidle UH; Ruiter DJ; van Muijen GN
Am J Pathol; 1994 Jan; 144(1):70-81. PubMed ID: 8291613
[TBL] [Abstract][Full Text] [Related]
9. Expression of active plasminogen activator inhibitor-1 reduces cell migration and invasion in breast and gynecological cancer cells.
Whitley BR; Palmieri D; Twerdi CD; Church FC
Exp Cell Res; 2004 Jun; 296(2):151-62. PubMed ID: 15149846
[TBL] [Abstract][Full Text] [Related]
10. LMO4 can interact with Smad proteins and modulate transforming growth factor-beta signaling in epithelial cells.
Lu Z; Lam KS; Wang N; Xu X; Cortes M; Andersen B
Oncogene; 2006 May; 25(20):2920-30. PubMed ID: 16331278
[TBL] [Abstract][Full Text] [Related]
11. Compound Astragalus and Salvia miltiorrhiza extract inhibits cell invasion by modulating transforming growth factor-beta/Smad in HepG2 cell.
Liu X; Yang Y; Zhang X; Xu S; He S; Huang W; Roberts MS
J Gastroenterol Hepatol; 2010 Feb; 25(2):420-6. PubMed ID: 19793165
[TBL] [Abstract][Full Text] [Related]
12. Influence of melanoma inhibitory activity on transforming growth factor-beta signaling in malignant melanoma.
Rothhammer T; Bosserhoff AK
Melanoma Res; 2006 Aug; 16(4):309-16. PubMed ID: 16845326
[TBL] [Abstract][Full Text] [Related]
13. Spitz naevi may express components of the plasminogen activation system.
Ferrier CM; Van Geloof WL; Straatman H; Van De Molengraft FJ; Van Muijen GN; Ruiter DJ
J Pathol; 2002 Sep; 198(1):92-9. PubMed ID: 12210068
[TBL] [Abstract][Full Text] [Related]
14. Differential roles of Src in transforming growth factor-ß regulation of growth arrest, epithelial-to-mesenchymal transition and cell migration in pancreatic ductal adenocarcinoma cells.
Ungefroren H; Sebens S; Groth S; Gieseler F; Fändrich F
Int J Oncol; 2011 Mar; 38(3):797-805. PubMed ID: 21225226
[TBL] [Abstract][Full Text] [Related]
15. Cytoplasmic localization of the oncogenic protein Ski in human cutaneous melanomas in vivo: functional implications for transforming growth factor beta signaling.
Reed JA; Bales E; Xu W; Okan NA; Bandyopadhyay D; Medrano EE
Cancer Res; 2001 Nov; 61(22):8074-8. PubMed ID: 11719430
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of urokinase-type plasminogen activator receptor induces apoptosis in melanoma cells by activation of p53.
Besch R; Berking C; Kammerbauer C; Degitz K
Cell Death Differ; 2007 Apr; 14(4):818-29. PubMed ID: 17110957
[TBL] [Abstract][Full Text] [Related]
17. Transforming growth factor beta inhibits plasminogen activator (PA) activity and stimulates production of urokinase-type PA, PA inhibitor-1 mRNA, and protein in rat osteoblast-like cells.
Allan EH; Zeheb R; Gelehrter TD; Heaton JH; Fukumoto S; Yee JA; Martin TJ
J Cell Physiol; 1991 Oct; 149(1):34-43. PubMed ID: 1834680
[TBL] [Abstract][Full Text] [Related]
18. Modulators of induction of plasminogen activator inhibitor type-1 in HepG2 cells by transforming growth factor-β.
Nakayama N; Nakamura T; Okada H; Iwaki S; Sobel BE; Fujii S
Coron Artery Dis; 2011 Nov; 22(7):468-78. PubMed ID: 21968503
[TBL] [Abstract][Full Text] [Related]
19. Ionizing radiation shifts the PAI-1/ID-1 balance and activates notch signaling in endothelial cells.
Scharpfenecker M; Kruse JJ; Sprong D; Russell NS; Ten Dijke P; Stewart FA
Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):506-13. PubMed ID: 19147015
[TBL] [Abstract][Full Text] [Related]
20. Expression of plasminogen activators and plasminogen activator inhibitors in cutaneous melanomas of transgenic melanoma-susceptible mice.
de Vries TJ; Kitson JL; Silvers WK; Mintz B
Cancer Res; 1995 Oct; 55(20):4681-7. PubMed ID: 7553649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
